PDF(Pubmed)
Abstract：
Numerous studies have manifested long noncoding RNAs (lncRNAs) as biomarkers to determine the prognosis of multiple myeloma (MM) patients. Nevertheless, the prognostic role of lncRNAs in MM is still ambiguous. Herein, we performed a meta-analysis to evaluate the predictive value of aberrantly expressed lncRNAs in MM.
A systemic literature search was performed in PubMed, EMBASE, Cochrane, and Web of Science databases until October 9, 2021, and the protocol was registered in the PROSPERO database (CRD42021284364). Our study extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), or event-free survival (EFS). Begg\'s and Egger\'s tests were employed to correct publication bias.
Twenty-six individual studies containing 3501 MM patients were enrolled in this study. The results showed that aberrant expression of lncRNAs was associated with poor OS and PFS of MM patients. The pooled HRs for univariate OS and PFS were 1.48 (95% CI = 1.17-1.88, p < 0.001) and 1.30 (95% CI = 1.18-1.43, p < 0.001), respectively, whereas the pooled HRs for multivariate OS and PFS were 1.50 (95% CI = 1.16-1.95, p < 0.001) and 1.59 (95% CI = 1.22-2.07, p < 0.001), respectively. Subgroup analysis suggested that MALAT1, TCF7, NEAT1, and PVT1 upregulation were associated with poor OS (p < 0.05), PVT1, and TCF7 upregulation were implicated with worse PFS (p < 0.05), while only TCF7 overexpression was correlated with reduced EFS (p < 0.05). Moreover, the contour-enhanced funnel plot demonstrated the reliability of our current conclusion, which was not affected by publication bias.
Aberrantly expressed particular lncRNAs are critical prognostic indicators in long-term survival as well as promising biomarkers in progression-free status. However, different cutoff values and dissimilar methods to assess lncRNA expression among studies may lead to heterogeneity.
A systemic literature search was performed in PubMed, EMBASE, Cochrane, and Web of Science databases until October 9, 2021, and the protocol was registered in the PROSPERO database (CRD42021284364). Our study extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), or event-free survival (EFS). Begg\'s and Egger\'s tests were employed to correct publication bias.
Twenty-six individual studies containing 3501 MM patients were enrolled in this study. The results showed that aberrant expression of lncRNAs was associated with poor OS and PFS of MM patients. The pooled HRs for univariate OS and PFS were 1.48 (95% CI = 1.17-1.88, p < 0.001) and 1.30 (95% CI = 1.18-1.43, p < 0.001), respectively, whereas the pooled HRs for multivariate OS and PFS were 1.50 (95% CI = 1.16-1.95, p < 0.001) and 1.59 (95% CI = 1.22-2.07, p < 0.001), respectively. Subgroup analysis suggested that MALAT1, TCF7, NEAT1, and PVT1 upregulation were associated with poor OS (p < 0.05), PVT1, and TCF7 upregulation were implicated with worse PFS (p < 0.05), while only TCF7 overexpression was correlated with reduced EFS (p < 0.05). Moreover, the contour-enhanced funnel plot demonstrated the reliability of our current conclusion, which was not affected by publication bias.
Aberrantly expressed particular lncRNAs are critical prognostic indicators in long-term survival as well as promising biomarkers in progression-free status. However, different cutoff values and dissimilar methods to assess lncRNA expression among studies may lead to heterogeneity.
摘要：
许多研究表明，长链非编码RNA（lncRNA）作为生物标志物来确定多发性骨髓瘤（MM）患者的预后。然而，lncRNAs在MM中的预后作用仍然不明确。在这里，我们进行了一项荟萃分析,以评估MM中异常表达lncRNAs的预测价值.
在PubMed中进行了系统的文献检索，EMBASE,科克伦,和WebofScience数据库，直到2021年10月9日，该协议已在PROSPERO数据库（CRD42021284364）中注册。我们的研究提取了总生存期(OS)的风险比(HR)和95%置信区间(CI)，无进展生存期（PFS），或无事件生存（EFS）。Begg\和Egger\的测试被用来纠正出版偏见。
本研究纳入了26项包含3501MM患者的个体研究。结果显示，lncRNAs的异常表达与MM患者的不良OS和PFS相关。单变量OS和PFS的合并HR分别为1.48（95％CI=1.17-1.88，p<0.001）和1.30（95％CI=1.18-1.43，p<0.001），分别,而多变量OS和PFS的合并HR分别为1.50（95%CI=1.16-1.95，p<0.001）和1.59（95%CI=1.22-2.07，p<0.001），分别。亚组分析提示MALAT1、TCF7、NEAT1和PVT1上调与不良OS相关(p<0.05),PVT1和TCF7上调与较差的PFS有关（p<0.05），而只有TCF7过表达与EFS降低相关(p<0.05)。此外，轮廓增强漏斗图证明了我们当前结论的可靠性，不受发表偏倚的影响。
异常表达的特定lncRNAs是长期生存的关键预后指标，也是无进展状态的有希望的生物标志物。然而,不同的截止值和不同的方法来评估lncRNA表达在研究中可能会导致异质性.
在PubMed中进行了系统的文献检索，
本研究纳入了26项包含3501MM患者的个体研究。
异常表达的特定lncRNAs是长期生存的关键预后指标，也是无进展状态的有希望的生物标志物。
